688192 Stock Overview
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥42.16 |
| 52 Week High | CN¥51.15 |
| 52 Week Low | CN¥24.82 |
| Beta | 0.23 |
| 1 Month Change | -8.51% |
| 3 Month Change | 18.83% |
| 1 Year Change | -10.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688192 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.7% | -1.9% | -1.0% |
| 1Y | -10.1% | -19.6% | 10.8% |
Return vs Industry: 688192 exceeded the CN Biotechs industry which returned -18.4% over the past year.
Return vs Market: 688192 underperformed the CN Market which returned 12.3% over the past year.
Price Volatility
| 688192 volatility | |
|---|---|
| 688192 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688192 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688192's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 807 | Zhang Xiaolin | www.dizalpharma.com |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Fundamentals Summary
| 688192 fundamental statistics | |
|---|---|
| Market cap | CN¥17.52b |
| Earnings (TTM) | -CN¥837.22m |
| Revenue (TTM) | CN¥389.64m |
45.0x
P/S Ratio-20.9x
P/E RatioIs 688192 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688192 income statement (TTM) | |
|---|---|
| Revenue | CN¥389.64m |
| Cost of Revenue | CN¥13.65m |
| Gross Profit | CN¥375.99m |
| Other Expenses | CN¥1.21b |
| Earnings | -CN¥837.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01 |
| Gross Margin | 96.50% |
| Net Profit Margin | -214.87% |
| Debt/Equity Ratio | 187.4% |
How did 688192 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 05:08 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dizal (Jiangsu) Pharmaceutical Co., Ltd. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Ziyu He | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |